A Reason for Optimism
This is the 13th anniversary of my husband's death. It may sound like a contradiction, but it is a reason [...]
ECAN Experts cited in US News & World Report
"Esophageal Cancer: What to Know" is a new report from U.S. News & World Report by contributing writer David Levine. [...]
FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Hope is Important
These are challenging times. And we at ECAN are keeping our focus trained on the positive difference we can [...]
2020 Wins for Esophageal Cancer Patients
Despite the challenges of 2020, progress was achieved in the battle to end Esophageal Cancer - much of it thanks [...]
Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
ECAN Advocates Convince Congress to Include Esophageal Cancer in a Multi-Million Dollar Research Fund
For the second year in a row, thousands of ECAN advocates made their voices heard and convinced lawmakers in the [...]
FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC). It [...]